EcoDrugPlus

Protein Tyrosine Kinase 2

Ensembl ID : ENSLBEG00000026333
Gene Symbol: PTK2
3 Cross references
246 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSLBEG00000023042
Gene Symbol: PTK2
1 Cross references
239 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSLBEG00000001622
Gene Symbol: PTK2B
3 Cross references
195 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSLBEG00000009780
Gene Symbol: PTK6
3 Cross references
159 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSLBEG00000014581
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSLBEG00000012624
Gene Symbol: PTPRB
3 Cross references
203 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSLBEG00000023572
Gene Symbol: LOC109996231
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSLBEG00000019497
Gene Symbol: P2RX3
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSLBEG00000023311
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSLBEG00000018853
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Putative N-Acetylated-Alpha-Linked Acidic Dipeptidase

Ensembl ID : ENSLBEG00000027990
Gene Symbol: LOC109989845
3 Cross references
339 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSLBEG00000008953
Gene Symbol: P2RY4
2 Cross references
165 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).